EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Daiichinkyo Co's Enterprise Value is 円4,714,501 Mil.
Daiichinkyo Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円-71,347 Mil. Therefore, Daiichinkyo Co's EV-to-FCF for today is -66.08.
The historical rank and industry rank for Daiichinkyo Co's EV-to-FCF or its related term are showing as below:
TSE:4568'
s EV-to-FCF Range Over the Past 10 Years
Min: -115.78 Med: 32.11 Max: 537.72
Current: -65.79
During the past 13 years, the highest EV-to-FCF of Daiichinkyo Co was 537.72. The lowest was -115.78. And the median was 32.11.
TSE:4568's EV-to-FCF is ranked worse than 100% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.765
vs TSE:4568: -65.79
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Daiichinkyo Co's PE Ratio (TTM) for today is calculated as:
Daiichinkyo Co's share price for today is 円2730.50.
Daiichinkyo Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円140.370.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Daiichinkyo Co EV-to-FCF Related Terms
Daiichinkyo Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Daiichinkyo Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's EV-to-FCF falls into.
Daiichinkyo Co's current Enterprise Value is 円4,714,501 Mil.
Daiichinkyo Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-71,347 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiichinkyo Co (TSE:4568) has a EV-to-FCF of -66.08 as of Jul. 10, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Daiichinkyo Co and its competitors. According to the industry distribution chart, Daiichinkyo Co ranks #999999 out of 562 companies in the Drug Manufacturers industry.
Is Daiichinkyo Co's EV-to-FCF too high?
Daiichinkyo Co's current EV-to-FCF is -66.08. Based on the distribution chart, Daiichinkyo Co ranks #999999 out of 562 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Daiichinkyo Co has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiichinkyo Co's EV-to-FCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Daiichinkyo Co ranks #999999 out of 562 companies for EV-to-FCF. This places Daiichinkyo Co in the lower half of its industry. The industry median EV-to-FCF is 20.77. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.77, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Daiichinkyo Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiichinkyo Co's current EV-to-FCF is -66.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiichinkyo Co stock overvalued right now?
Based on GuruFocus' analysis, Daiichinkyo Co (TSE:4568) is currently considered Significantly Undervalued. The stock's GF Value™ is 円6,101.95, compared to a current price of 円2,730.50 — trading 55.3% below its estimated fair value. The current EV-to-FCF is -66.08. Daiichinkyo Co's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Daiichinkyo Co (TSE:4568), the current EV-to-FCF is -66.08 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daiichinkyo Co (TSE:4568) Overvalued in 2026?
Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued.
The current stock price of 円2,730.50 is trading 55.3% below its estimated GF Value™ of 円6,101.95.
GuruFocus considers Daiichinkyo Co to be Significantly Undervalued.
Key valuation signals for TSE:4568:
EV-to-FCF: -66.08
GF Value™: 円6,101.95 vs. price of 円2,730.50 (55.3% below fair value)
No single metric tells the full story. See the TSE:4568 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
80GF Score
Get the complete analysis for TSE:4568
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4568 has been successfully added to your 
